Study to Assess Neoadjuvant Durvalumab (D) and Platinum-Based Chemotherapy (CT), Followed by Either Surgery and Adjuvant D or CRT and Consolidation D, in Resectable or Borderline Resectable Stage IIB-IIIB NSCLC (MDT-BRIDGE)

To be part of this study, you would need to have non-small cell lung cancer that is at stage IIB, IIC, or IIIB (specifically where it has spread to certain lymph nodes, called N2). Doctors would need to confirm that your cancer can either be completely removed by surgery, or that it’s on the borderline of being removable, after a discussion by a team of specialists.

It's important that you haven't received any previous treatment for your lung cancer. You must also be well enough to have surgery, with your heart and lung function being good enough. Your doctor will need to check that your cancer doesn't have certain gene changes (specifically EGFR mutations or ALK translocations).

There are also some reasons why someone couldn't join. For example, if your cancer has already spread to distant parts of your body (Stage IIIC), or if you have specific health conditions that make surgery unsafe. Being pregnant or breastfeeding, or having certain infections like HIV or active hepatitis, would also mean you couldn't take part. The research team will do a full health check to make sure the study is right for you.

If you join this study, your journey will begin with two cycles of treatment, each lasting three weeks. This involves receiving the study drug, durvalumab, along with standard chemotherapy, both given through a drip into your vein. Afterwards, a team of specialists will assess whether surgery to remove your tumour is possible.

If surgery is recommended, you'll have one or two more cycles of the durvalumab and chemotherapy combination, followed by the surgery. After your recovery from surgery, you'll then receive durvalumab alone every four weeks for up to a year, or until your cancer shows signs of progressing. If surgery isn't an option, you will have about six weeks of daily chemotherapy and radiation therapy. After this, you would then receive durvalumab alone every four weeks, also for up to a year or until your cancer progresses. Throughout the study, you'll have regular hospital visits for assessments, scans, and blood tests to monitor your health and how well the treatment is working. The total time you're on treatment and follow-up will vary depending on your individual response and treatment path.